The Discovery of Endorphins

For years it had been suspected that opiates had specificbinding sites in the brain. There were several attempts tolocate these sites, but the existing technologies were unable todistinguish between the non specific binding to tissue and thespecific binding to receptors. It must be mentioned here thatthe first attempt to actually measure specific opiate bindingwas in the laboratory of Dr. Vincent Dole (Ingolia & Dole,1970). Although the technology was not available at that timehe laid the foundations for the discovery of opiate receptors.

By the early 1970s scientific technology had evolved to thepoint where the discovery of opiate binding sites seemed almostinevitable. The first to shake the scientific community wasSolomon Snyder and his student, Candice Pert of John HopkinsUniversity (Pert & Snyder, 1973). Using a technique developedby Avram Goldstein of Stanford University, Snyder and Pertlocated the elusive opiate receptor (Goldstein, Lowney & Pal,1971). That same year two other groups headed by Eric J. Simonof New York University (1973) and Lars Terenious in Uppsala,Sweden (1973) demonstrated specific opiate binding in nervoustissue. The treasure Hunt had begun! “For why,” Goldsteinasked, “would God have made opiate receptors unless he had alsomade an endogenous morphine-like substance?”

In the mid-1960s Choh Li of the University of California atBerkeley had isolated a pituitary hormone which he namedB-Lipotropin (Li, 1964). He noted that one portion of thishormone had analgesic properties. One year after the discoveryof the receptor sites John Hughes at the laboratory of HansKosterlitz in Aberdeen, Scotland reported the existence of anendogenous morphine-like substance which they later purified andnamed Enkephalin for “in the head” (Hughes, 1975a; Hughes,1975b; Kosterlitz, 1976) The Aberdeen group recognized that thepeptide sequence of Enkephalin was contained within Li’s B-Lipotropin. Li would later name the other endogenousmorphine-like peptides, which also come from his pituitaryhormone, Endorphin for “morphine within.”

Today the term opioid is used for all endogenous morphine-likesubstances, including Dynorphin another brain opioid peptidesystem found by Avram Goldstein (Goldstein, Tachibana, Lowney,Hunkapiller & Hood, 1979). Other psychoactive peptides have beendiscovered and isolated using the techniques developed in theselaboratories. In 1978 Solomon Snyder, John Hughes and HansKosterlitz shared the Lasker Award for their discoveries. Paralleling the discovery of Enkephalins, Endorphins and opiatereceptors have been advances in the field of neuroscience. These advances have led to many exciting discoveries andgenerated a new interest in the functioning of the brain. Wehave entered a new era in our understanding of human behavior.


References

  • Goldstein, A.; Lowney, L.I. and Pal, B.K.
    Stereospecific andnon stereospific interactions of the morphine congenerlevorphanol in sub cellular fractions of mouse brain.

    Proceedings of the National Academy of Science USA 1971 68:1742-1747.

  • Goldstein, A.; Tachibana, S.; Lowney, L.I.; Hunkapiller M. and Hood, L.
    Dynorphin-(1-13), an extraordinarily potent opioid

Similar Posts

  • Tag: ADA

    Admin 12/09/2022

    DOJ publishes guidance on Opioid Use Disorder and the Americans with Disabilities Act April 15, 2022 “The opioid crisis poses an extraordinary challenge to communities throughout our country. The Department of Justice (the Department) has responded with a comprehensive approach prioritizing prevention, enforcement, and treatment. This includes enforcing the Americans with Disabilities Act (Ada), which…

  • Category: AATOD

    Admin 12/26/2021

    Congratulations to Sara Gefvert, the 2022 Lane/Holden Award Winner! November 2, 2022 The 2022 Richard Lane/Robert Holden Patient Advocacy Award was presented at an Awards Reception held in conjunction with the 2022 Conference of the American Association for the Treatment of Opioid Dependence (AATOD) in Baltimore, Maryland on November 2, 2022. Richard Lane/Robert Holden Patient…

  • CERTIFIED METHADONE ADVOCATE (CMA)-1

    Admin 02/22/2023

    The Advocacy Training Session The training for certification includes a variety of topics to give advocates a well-grounded understanding of methadone treatment, research, regulations and laws that protect methadone patients and programs. Addiction and Methadone The biological constructs of addiction will be explained in a way that can be understood by lay people (i.e. opiate receptors,…

  • References

    Admin 09/12/2022

    Batki, S.L.  Treatment of intravenous drug users with AIDS:  The role of methadone maintenance.  Journal of Psychoactive Drugs 1988 20: 213-216. Legal Action Center. Beazer vs New York City Transit Authority: A Landmark Decision on Methadone Maintenance [Report].  New York: National Institute on Drug Abuse, 1975.   Des Jarlais, D.C.; Friedman, S.R.; Novick, D.M. et…

  • Stigma: The Invisible Barrier by Herman Joseph and Joycelyn Woods

    Admin 12/13/2021

    Herman Joseph, Ph.D. is a member of NAMA’s Advisory Board and has been involved in methadone treatment and research since it’s beginning. This article is excerpted from Herman Joseph’s dissertation on stigma. Methadone maintenance treatment has been subjected to professional trivialization and misunderstandings, has consistently received sensationalized negative media coverage and been the target of…

  • What is NAMA

    Admin 06/14/2023

    NAMA IS COMMITTED TO: Promoting quality methadone maintenance treatment as the most effective modality for the treatment of heroin addiction.  Working to dispel the ignorance regarding MMT which plagues both treatment professionals and the general public.  Fighting discrimination perpetrated against methadone maintenance patients.  Struggling to destigmatize the treatment which has given us back our lives. …